The resistance of Plasmodium falciparum to artemisinin has been identified in Asia and some parts of Africa. The drug resistance of P. falciparum will be an obstacle to the successful elimination of malaria by 2025. Whole-genome sequencing of the artemisinin-resistant parasite line revealed mutations on the k13 gene associated with drug resistance in P. falciparum. To understand the artemisinin resistance of the imported P. falciparum cases from Africa, the mutations in the k13 gene in parasites from imported malaria cases in Guangxi Province were detected and the treatment efficiency of artesunate monotherapy was observed.
Ivermectin mass drug administration (MDA) in humans to reduce malaria vectors is yet another use for this remarkable medicine whose discoverers shared the 2015 Nobel Prize in Medicine with the discoverer of artemisinin.
Exports of artemisinin derivatives for China have been transforming from API-dominated to FPP-dominated.
The fight against mosquito-borne diseases is a challenge of huge public health importance.
With proper malaria diagnosis, SP may still be used as a rational anti-malarial drug either as a single prescription or in combination with artemisinin.
Whole-genome sequencing technologies are being increasingly applied to Plasmodium falciparum clinical isolates to identify genetic determinants of malaria pathogenesis.
Paul Russell’s Man’s Mastery of Malaria (1), written in 1955, opens with these wistful words: “While keeping in mind the realities, one can nevertheless be confident that malaria is well on its way toward oblivion
Following a decade of gains in malaria control, two divergent prospects are emerging:
Artemisinin, also known as qinghaosu, is a sesquiterpene lactone endoperoxide extracted from the plant Artemisia annua L, an herb employed in traditional Chinese medicine.
These results highlight the normal distribution of early parasitological responses following ACT, and the influence that heterogeneity in study design, host and parasite factors have in confounding a surveillance system based on Day 3 parasite positivity.